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Osteocalcin: A non-invasive index of metabolic bone disease in patients
treated by CAPD. Serum osteocalcin has been found to correlate with
bone formation. However, present literature gives only limited data on
osteocalcin and bone histomorphometry in patients undergoing peritoneal
dialysis. This study assessed serum osteocalcin, dialysate osteocalcin,
peritoneal clearance of osteocalcin (Cl-osteocalein) and mass transfer of
osteocalcin (MT-osteocalcin), and evaluated relationships between these
values and bone histomorphometry. Eighteen patients were treated by
continuous ambulatory peritoneal dialysis (CAPD). Bone biopsies, serum
and dialysate osteocalcin, serum levels of parathyroid hormone, alkaline
phosphatase, aluminum, phosphate, Ca2 and vitamin D3 metabolites
were measured at the start and in 10 of the patients a year later. Serum
osteocalcin was found to be elevated. Osteocalcin was detected in the
dialysate resulting in significant values of Cl-osteocalcin and MT -
osteocalcin. Serum and dialysate levels of osteocalcin correlated signi-
cantly (r = 0.66, P c 0.001) and like MT-osteocalcin with serum levels of
alkaline phosphatase and PTH. Histomorphometiy showed that osteitis
fibrosa was the predominant bone disease detected. Serum concentration
of osteocalcin correlated with osteoid thickness, eroded and osteoclast
surfaces, aluminum staining, and some of the bone dynamic parameters.
Dialysate osteocalcin, MT-osteocalcin, PTH and alkaline phosphatase
correlated with practically the same histomorphometric parameters as
serum osteoealcin. No correlations were seen between Cl-osteocalcin and
any histomorphometric parameters. Serum osteocalcin was elevated above
the normal range, and significant positive correlations between serum
osteocalcin and bone formation parameters were found. Serum osteocal-
cm correlated with almost the same histomorphometric parameters as
PTH. Thus, serum levels of P1'H and osteocalcin gave additional infor-
mation to one another as non-invasive parameters in this group of
patients. Hence, serum usteocalcin is a valuable non-invasive index of
metabolic bone disease in patients treated by CAPD. The transperitoneal
removal of osteocalcin does not appear to be clinically significant.
With the discovery of osteocalcin another non-invasive tool for
evaluation of bone metabolism became possible [1, 21. This
protein, which constitutes 20 to 25% of non-collagen bone
protein, is exclusively synthesized by osteoblasts and is a sensitive
and specific humoral marker of bone formation. It is secreted into
bone matrix, where it binds to hydroxyapatite and later incorpo-
rates into bone matrix [2]. However, a fraction of the newly
synthesized protein escapes to serum ("spill-over") where levels
have been found to correlate with histomorphometric indices of
bone formation [3], a parameter otherwise not easily studied
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except through kinetic techniques or by an invasive approach like
bone biopsy.
Osteocalcin is normally filtered by the kidneys and thereafter
eatabolized to its constituent amino acids [4]. An increase in
circulating osteocalcin could therefore reflect increased skeletal
production, decreased renal clearance, or both. In conservatively
treated uremic and hemodialyzed patients, a direct relationship
between serum levels of osteocalein and histological parameters
of bone formation has been observed [5—7]. Studies in adults and
children have shown that serum levels of osteocalcin in patients
undergoing continuous ambulatory peritoneal dialysis (CAPD)
were significantly lower than corresponding concentrations in
hemodialysis patients [8, 9]. This observation could be explained
by the finding of higher concentrations of osteoealcin in perito-
neal dialysate effluent compared to concentrations in the effluent
from hemodialysis [10—12]. However, only limited data dealing
with osteoealcin measurements in CAPD are available [4, 7, 8,
10—12]. Nevertheless, to the best of our knowledge, no data
including serum and dialysate levels of osteocalcin, peritoneal
mass transfer and clearance values of this protein in correlations
to bone histomorphometry have yet been published.
The aim of the present investigation therefore was to: (1) assess
values of serum osteocalcin, dialysate levels of osteocalein as well
as peritoneal clearance and mass transfer of osteocalcin in adults
treated by CAPD; (2) evaluate the relationship between the
values of osteocalcin and bone histomorphometry with respect to
renal osteodystrophy as a non-invasive predictor of bone histol-
ogy; and (3) determine the correlations, if any, between osteoeal-
cm levels and other humoral parameters of bone metabolism in
CAPD patients not receiving vitamin D3 analogues.
Methods
Subjects
A group of 5 women and 13 men maintained on CAPD for
19.7 21.3 months (range 1 to 87) was studied. Mean age was
62.0 14.4 years (range 34 to 83). Primary renal diseases were
diabetic nephropathy in six patients, chronic glomerulonephritis
in four, interstitial nephropathy in three, hypertensive nephropa-
thy in two, chronic pyelonephritis in one, obstructive nephropathy
in one and systemic lupus in one. Clinical evidence of cardiac
failure, peripheral edema or nephrotic syndrome was not present
in any subject. Residual kidney function was not evaluated. Three
of the five female patients were postmenopausal; the two others
had developed amenorrhea during the course of their chronic
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renal failure. None of the patients was nephrectomized, parathy-
roidectomized, oophorectomized or had signs of liver disease or
malabsorption. Moreover, none had received a kidney transplant
earlier and none had been immobilized before the current study.
None took vitamin D3 analogues of any kind, calcium supple-
ments, steroids, estrogens, coumarins, anticonvulsants or medica-
tions known to interact with calcium, vitamin D3 and osteocalcin
levels, and only the patient with systemic lupus had received
steroids and cytostatic therapy earlier for his primary disease.
None had peritonitis episodes for at least the preceding two
months before study periods. None used drugs known to influence
peritoneal permeability. No patient had ever been exposed to
dialysis solutions containing acetate or chiorhexidine intraperito-
neally or had undergone abdominal surgery involving the perito-
neal cavity.
All patients received a diet containing a daily intake of at least
1 g of protein per kg body wt and without sodium restriction.
Aluminum containing phosphate binders were only prescribed
when repeated measurements of serum phosphate were >2.0
mmol/liter. Six patients had to consume aluminum-containing
phosphate binders.
All gave informed consent according to the Declaration of
Helsinki II. No side effects or complications were observed during
the investigation.
Dialysis technique
CAPD was performed by standard technique. The dialysis fluid
contained 1.75 mmol/liter calcium and 0.75 mmol/liter of magne-
sium (Dianeal, Baxter Healthcare Corporation). The choice of
dextrose solution (1.5% or 4.25%) was based on general fluid
balance. None of the patients had "dry nights."
Investigations
Studies were performed during 24 hour periods with patients on
their usual regime of CAPD. Peritoneal dialysate effluents and
blood samples were drawn at the end of each study period when
transiliac bone biopsies were also performed.
The effluent was mixed and measured. Portions were stored at
—20°C with blood samples for later assay of osteocalcin.
Laboratory procedures
Plasma concentrations of alkaline phosphatase, total calcium
and phosphate were determined by standard methods (SMAC,
Technicon Instruments Corporation, Tarrytown, New York,
USA). Ionized calcium was analyzed at pH 7.4 using an ionized
calcium analyzer (ICA1, Radiometer, Copenhagen, Denmark).
Immunoreactive determination of intact parathyroid hormone
(PTH) was performed using the Allegro intact PTH kit (Nichols
Institute Diagnostics, San Juan Capistrano, California, USA).
This system has a sensitivity of 1 pg/mI (0.1 nmol/liter) and is
highly specific for only the biologically active and intact PTH
molecule. Normal range, intra-assay and interassay coefficients of
variation were 1.1 to 4.8 pmol/liter, 1.8% and 5.6%, respectively.
Serum magnesium was determined by atomic absorption spec-
trophometiy. Serum aluminum was analyzed in duplicate samples
by Zeeman-corrected electrothermal atomic absorption spec-
trometiy [13]. The limit of detection obtained by the method was
1.5 g/liter. Bone aluminum concentrations were measured from
the remains of plastic embedded biopsies used for the bone biopsy
analysis. The methods have previously been described [14].
Plasma levels of osteocalcin were assayed using a solid phase
enzyme-linked immunosorbent assay [15]. Purified osteocalcin
was prepared from femoral shafts of calves, and conjugated for
immunization in rabbits. The lower detection limit of this ELISA
assay was less than 0.5 pg/liter (0.172 nmol/liter osteocalcin = 1
ng/ml osteocalcin). For serum osteocalcin the normal range used
was 7.1 to 12.1 tgIl, without sex or age variation [15]. The
intra-assay and interassay coefficients of variation were 6.0% and
5.3%, respectively. All samples were analyzed in duplicate.
1,25(OH)2D3, 25(OH)D3 and vitamin-D-binding protein (DBP)
were determined by previously described methods [16].
Bone biopsy and histomorphometiy
Eighteen patients underwent a bone biopsy at the start of the
study and 10 had one performed a year later. Thus, a total of 28
bone biopsies were obtained. One of the 10 biopsies performed at
the end of the study was taken postmortem. The transiliac
approach at the anterior iliac crest was used and performed under
local analgesia using a Bordier trocar with an internal diameter of
8 mm. Prior intravital tetracycline double-labeling with tetracy-
cline and oxytetracycline on a 2/11/2 day basis (250 mg tetracycline
twice daily for 2 days; 11 days without medication, followed by 250
mg oxytetracycline twice daily for another 2 days) was used.
Biopsies were obtained three to four days after the last oral doses
of oxytetracycline. The samples were fixed in 70% ethanol and
prestained by the Villanurva method for 72 hours before plastic
embedding [17]. Five micrometer thin sections were cut by a Jung
Universal microtome 1150/autocut. Sections were examined with-
out further staining or were stained with the Masson Trichrome
for evaluation of osteoid and the ammonium aurine tricarboxylic
acid (Aluminon) which stains specifically for aluminum [18].
Three groups of sections spaced approximately 200 m apart were
taken from each biopsy, and except for trabecular and cortical
areas, which were measured in one section only, all variables
representan average value for all trabecular and cortical bone in
three sections. The intraobserver variation for most variables was
between 5 to 15% [19].
The histomorphometric analysis was made with a Morphomat
30 (Zeiss, Germany) digitizing analyzer and Olympus BH2 micro-
scope. Conventional bone histomorphometry, including staining
for aluminum, definitions and normal values of the histomorpho-
metric data, was performed as previously described [14, 20, 21].
The measurements included trabecular bone volume as percent-
age of total tissue volume, osteoid volume as percentage of
trabecular bone volume and osteoid thickness, osteoid surface,
eroded surface and osteoclast surface all as percentage of total
surface. Osteoclast surface was defined as the percentual length of
osteoclast covered resorption surface. Cortical thickness was
measured by dividing cortical area by cortical length. Cortical
porosity was defined as cortical bone area as a percentage of total
cortical area. Trabecular bone thickness was defined as twice
tracecular bone area divided by trabecular bone perimeter length.
Tetracycline labeled biopsies were evaluated under fluorescent
light, enabling a quantitative measure of bone formation rate and
bone mineralization. Tetracycline labeled surfaces were defined
as the length of double tetracycline labeled surface plus one-half
length of single labeled surface. In patients where no marker
interval could be observed due to low bone formation, the
mineralization appositional rate was conventionally defined as 0.1
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tm/day and the mineralization lag time as 100 days minimum.
The following diagnostic criteria were used:
Osteitis fibrosa. Osteoclast surface >0.65% (that is, length of
osteoclast covered surface as a percentage of total bone surface),
normal mineralization Jag time (<100 days), varying degrees of
dissecting resorption and peritrabecular fibrosis and increased
turnover in tetracycline labeled biopsies.
Mixed uremic osteodystrophy. Biopsies with increased osteoclast
surface (>0.65%) and increased mineralization lag time (>100
days).
Osteomalacia. Biopsies with normal osteoclast surface
(<0.65%), osteoid thickness (>15 j.m) and increased mineraliza-
tion lag time (>100 days).
Adynamic lesion. Biopsies with increased mineralization lag
time (>100 days) but normal osteoclast surface (<0.65%) and
normal osteoid thickness (<15 sm).
Osteopenia. Biopsies with reduced trabecular bone volume
(<15% of total bone area) but otherwise with normal bone
parameters.
Normal. Biopsies with none of the above-mentioned features.
Aluminum staining was defined semiquantitatively as absent
(0), light (1), moderate (2) or heavy (3). Patients with osteoma-
lacia or adynamic lesion and histochemical aluminum deposition
(light, moderate or heavy) on the mineralization front were
classified as having aluminum related bone disease.
Calculations
Peritoneal clearances (Clv) were calculated using the standard
formula:
Dialysate concentration Drainage volume
x
Serum concentration Study penod
Peritoneal mass transfer (MT) of the solutes was calculated
according to the formula:
MT = C x V1 - C0 X V0
where C1 is the concentration in the inflow, V1 is the volume in the
inflow, C0 the concentration in the outflow and V0 the volume in
the outflow. MT was considered positive when a gain was
observed and negative in case of net removal from the body. The
instilled volume per exchange was assumed to be 1050, 1550 or
2050 ml in bags containing 1000, 1500 or 2000 ml dialysis solution,
respectively.
Statistical analysis
Data were analyzed parametrically and compared using Stu-
dent's t test. Variables were correlated using conventional regres-
sion analysis and Student's t-test. For variables not normally
distributed, comparison using the Mann-Whitney rank sum test
was used. To develop an algorithm to predict the MD analysis of
variance for all significantly correlated variables, stepwise variable
selection using the F test was performed. The variable with the
highest F-ratio was entered into the model, and the process was
repeated as long as the new variable added significantly to the
model. At each stage checks were made to see that previously
selected variables were still significant; variables that had become
insignificant were removed. Only F-ratios above 4.0 were allowed.
When all significant variables had been selected, the final model
was determined using the Graham-Schmidt algorithm.
Results
Biochemical parameters
Biochemical parameters including serum, dialysate, peritoneal
clearance (Clv) and peritoneal mass transfer (MT) levels of the
non-invasive markers of bone metabolism at start and end of the
study are reported in Table 1. Mean levels of serum osteocalcin
were elevated above the normal range at baseline and one year
later (Table 1). Moreover, significant amounts of osteocalcin were
detected in the dialysate effluent, both at baseline and after one
year, resulting in substantial peritoneal clearances of osteocalcin
(Cl-osteocalcin) and peritoneal mass transfer values of osteocal-
cm (MT-osteocalcin; Table 1). Mean values of serum levels of
PTH, magnesium and aluminum were all increased at the time of
both evaluations (baseline and one year later). Serum concentra-
tions of 1,25(OH)2D3 were below the normal range, adjusted for
sun exposure and age (Table 1). No significant changes between
parameters given in Table 1 at baseline and one year later were
found. No correlations were found between dialysate osteocalcin
values, inflow volume and drained volume of dialysate effluent.
Humoral parameters
Linear correlations between serum, dialysate, Cl-osteocalcin
and MT-osteocalcin levels and other humoral parameters are
shown in Table 2. Thus, serum osteocalcin, dialysate osteocalcin
and MT0-osteocalcin levels significantly correlated statistically
with serum levels of alkaline phosphatase and PTH (Table 2).
Also a statistically significant correlation between serum osteocal-
cm and MT-osteocalcin was found (r = 0.55, P < 0.01). No
correlations were found between serum osteocalcin levels and
serum values of calcium, Ca2, HCO3, magnesium, aluminum and
vitamin D3 parameters. Furthermore, serum and dialysate levels
of osteocalcin correlated significantly (r = 0.66, P < 0.001). Also
dialysate osteocalcin was significantly correlated with serum levels
of alkaline phosphatase and PTH (r 0.70, P < 0.001 and r =
0.69, P < 0.001, respectively).
Bone histology
The distribution of bone histology is given in Figure 1. No
specific etiology of renal disease was associated with any one of
the bone diagnoses. Osteitis fibrosa was the predominant biopsy
diagnosis. Six patients had a normal bone biopsy diagnosis, only
one of these six patients had a consistent bone diagnosis at
baseline evaluation and the year later (Fig. 1). Two of the five
patients having adynamic bone lesion had diabetes mellitus. Only
one of these patients had aluminum staining in his bone biopsy.
None in the adynamic group had high serum PTH levels.
Bone histomorphometiy
In Table 3 bone histomorphometric parameters at baseline, the
year after for patients evaluated with repeated bone biopsies and
the average values for all patients evaluated are given. Significant
differences between parameters at baseline and the year after
were only found for tetracycline labeled surface and trabecular
bone volume (P < 0.05 for both).
Correlations between osteocalcin measurements, other markers
of bone metabolism and the bone histomorphometric parameters
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Table 1. Serum (S), dialysate (D), peritoneal clearance (Clv) and peritoneal mass transfer (MT) of non-invasive markers of bone metabolism in
patients undergoing peritoneal dialysis.
Parameters Time 0 year Time 1 year
S-osteocalcin 7.1—12.1 pg/liter Mean SD: 21.4 16.8 18.8 16.1
Range: 1.9—50.5 1.0—56.5
Median: 16.7 15.6
Quartiles: 6.0—39.0 9.7—19.1
D-osteocalcin ug/1iter Mean sc: 7.5 6.7 7.5 4.5
Range: 1.0—23.8 2.0—15.2
Median: 6.0 5.5
Quartiles: 3.3—9.6 4.7—11.2
C1-osteocalcin mi/mm Mean SD: 2.3 2.9 3.9 3.8
Range: 0.5—12.2 1.4—12.8
Median: 1.2 2.6
Quartiles: 1.0—1.9 1.7—4.5
MT-osteocalcin pg/24 h Mean SD: —48.3 47.2 —54.0 33.2
Range: —5.2—(—) 202.8 —18.4—(—) 112.5
Median: —33.3 —42.0
Quartiles: —19.5—(—) 57.5 —30.6—(—) 78.0
S-calcium 2.1 7—2.57 mmoi/liter Mean SD: 2.18 0.18 2.22 0.24
Range: 1.90—2.49 1.88—2.68
Median: 2.23 2.21
Quartiles: 1.99—2.31 2.03—2.33
S-Ca2 1.15—1.35 mmol/liter Mean SD: 1.14 0.07 1.11 0.09
Range: 1.04—1.27 1.02—1.23
Median: 1.14 1.10
Quartiles: 1.08—1.21 1.04—1.18
S-phosphate 0.79 —1 .51 mmol/liter Mean SD: 1.84 0.52 1.98 0.61
Range: 1.03—3.19 1.25—3.23
Median: 1.75 1.88
Quartiles: 1.63—2.01 1.60—2.22
S-alkaline phosphatase 80—275 U/liter Mean SD: 230 80 243 63
Range: 126—447 136—380
Median: 200 242
Quartiles: 171—302 199 —265
S-PTH 1.1—4.8pmol/iiter Mean SD: 22.8 25.8 18.8 8.9
Range: 0.5—131.6 9.7—40.3
Median: 16.7 16.4
Quartiles: 6.5—28.1 14.9—20.2
S-HCO3 23—35 mmolf liter Mean so: 24 3 23 2
Range: 20—32 20—26
Median: 24 23
Quartiles: 22—26 22—24
S-magnesium 0.61—0.85 mmol/liter Mean so: 1.14 0.21 1.10 0.12
Range: 0.80—1.66 0.98—1.35
Median: 1.10 1.08
Quartiles: 0.99—1.27 0.99—1.15
S-aluminum 0.0—0.6 wnoi/liter Mean SD: 1.6 2.0 1.8 2.5
Range: 0.1—9.6 0.2—7.4
Median: 0.85 0.7
Quartiles: 0.7—1.9 0.4—1.9
S-1,25(OH)2D3 24 —158 pmol/iiter Mean so: 18 6
Range: 12—33
Median: 16
Quartiles: 15—21
S-25(OH)D3 18.5—82.0 nmol/liter Mean SD: 29.8 20.7
Range: 3.6—76.0
Median: 21.5
Quartiles: 14.7—50.0
S-DBP 4.1—7.5 ,unol/liter Mean SD: 6.0 1.1
Range: 4.6—8.4
Median: 5.9
Quartiles: 5.4—6.2
No significant differences between levels found at baseline and at one year was found. Abbreviation is DBP, vitamin D3 binding protein. Quartiles
are the 25th and 75th percentiles.
are reported in Table 4. Serum osteocalcin correlated best with appositional rate, labeled surface, bone formation rate per unit of
eroded surface and osteoclast surface (P < 0.001 and P < 0.05, bone surface, bone volume and tissue volume, respectively). The
respectively; Table 4) and with bone dynamic parameters (mineral extent of aluminum deposits in bone (aluminum bone content)
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Serum
osteocalcin
Dialysate
osteocalcin
Cli,-
osteocalcin
MT,-
osteocalcin
S-calcium NS NS NS NS
S-Ca2 NS NS NS NS
S-phosphate NS NS NS NS
S-alk. phos.
r = 0.43 0.70 NS 0.55
= 2.1 4.5 2.9
P = 0.05 <0.001 <0.05
S-PTI-l
r = 0.55 0.69 NS 0.46
= 2.3 4.5 2.9
P < 0.05 <0.001 <0.05
S-HCO3 NS NS NS NS
S-magnesium NS NS NS NS
S-aluminum NS NS NS NS
S-1,25(OH)2D3 NS NS NS NS
S-25(OH)D3 NS NS NS
r= 0.57
t=
NS
2.4
0.05
NS
P<
S-DBP NS NS
Data at baseline and at one year were added.
Abbreviations are: 5, serum; D, dialysate; Cli,, peritoneal clearance;
MT, peritoneal mass transfer; DBP, vitamin D3 binding protein; NS, not
significant.
did not correlate with any of the measured bone markers,
although the qualitative assessment of aluminum deposits in bone
(aluminum staining) correlated negatively with serum osteocalcin
and serum total calcium (Table 4). Tetracycline labeled surface
correlated to a very high extent with serum and dialysate levels of
osteocalcin and serum PTH (tetracycline labeled surface = —3.15
+ 0.145 x serum osteocalcin + 0.409 X dialysate osteocalcin +
0.184 X serum PTH; r = 0.98) as shown in Figure 2, where
measured tetracycline labeled surface is illustrated in relation to
the predicted tetracycline labeled surface. Dialysate osteocalcin,
MT-osteocalcin, serum levels of PTH and alkaline phosphatase
correlated almost with the same histomorphometric parameters
as serum osteocalcin (Table 4). No correlations were seen be-
tween Cl-osteocalcin as well as serum aluminum levels and any of
the histomorphometric parameters listed (Table 4). Finally, a
negative correlation was found for osteoclast surface versus length
of uremia (r = 0.49, P < 0.05). Age correlated positively with
serum Ca2 (P < 0.05) and negatively with serum phosphate (P <
0.05), serum aluminum (P < 0.05), serum 1,25(OH)2D3 (P <
0.05), corrected apposition rate (P < 0.01), and bone formation
rate per unit of bone surface, bone volume and tissue volume,
respectively (P < 0.05 for all three).
Discussion
Many procedures have been used to assess bone metabolism
including humoral substances, radiological, radionuclear and den-
sitometric evaluations as well as scanning and bone histomor-
phometry. Although these procedures have provided important
information each method has limitations. Therefore, a sensitive
and specific non-invasive biochemical marker for bone metabo-
lism is needed. Alkaline phosphatase has been widely used as such
a marker. However, osteocalcin has the important advantage over
alkaline phosphatase in that it is a specific marker for bone
!
metabolism only. Unlike alkaline phosphatase, its plasma level is
not contributed to by any other cell type than the osteoblast. In
addition, it has been shown that alkaline phosphatase was unable
to differentiate between patients with low bone turnover and
those with high bone turnover [22]. Some authors have claimed
that osteocalcin has the same sensitivity but higher specificity than
PTH for prediction of bone formation status [22]. We found that
serum osteocalcin and PTH levels gave supplementary informa-
tion to one another. As previously observed [5, 7, 9, 10, 22], major
correlations between serum, dialysate, Cl-osteocalcin and MT-
osteocalcin levels and other humoral parameters related to bone
metabolism were found. In agreement with others [5, 7, 10, 22],
serum osteocalcin was significantly correlated with serum alkaline
phosphatase and serum PTH. Moreover, we observed that dialy-
sate osteocalcin and MT-osteocalcin also correlated with serum
alkaline phosphatase and serum PTH. However, unlike to Klein et
a! [10], we were unable to find any correlation between serum
osteocalcin and serum calcium.
Another important topic has been the probable influence of the
dialysis modality (peritoneal vs. hemodialysis) on osteocalcin
concentrations. Some authors have reported no differences in
serum osteocalcin levels in patients undergoing CAPD versus
hemodialysis [9}. Others found lower serum levels in CAPD
patients due to a significant peritoneal removal of osteocalcin [4,
81. This is consistent with the view that some proteins with a
molecular weight in the range of osteocalcin's and PTH are not
removed as effectively by hemodialysis as by CAPD [23]. We
found that the transperitoneal removal of osteocalcin did not
appear to alter osteocalcin levels in blood.
There is still controversy over whether increased serum osteo-
calcin reflects increased osteoblast production or decreased renal
clearance of this protein. Unfortunately, residual kidney function
and urine output was not monitored in the present study. Thus, a
possible renal excretion of osteocalcin could not be evaluated.
However, as the majority of our bone biopsies showed high
Table 2. Correlations between osteocalcin measurements and other
biochemical markers of bone metabolism
Mixed uremic
osteodystrophy
Osteitis fibrosa
Baseline One year
Normal
Aplastic disease
Aluminum-related
bone disease .
Fig. 1. The distribution of bone biopsy diagnosis at baseline, one year later
and the changes over time. Each dot represents one patient. Patients
biopsied twice are indicated with two dots connected with a line, while a
single dot represents patients only having one bone biopsy taken.
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Table 3. Bone histomorphometric parameters (mean SD with ranges given in parentheses) at baseline and one year later in patients on
peritoneal dialysis biopsied twice
Parameters units All patients Baseline One year
Osteoid — — —
Osteoid thickness mz 9.7 3.0 9.8 2.9 (6.0 —15.4) 9.8 3.4 (6.0—16.3)
Osteoid surface % 25.0 15.5 23.3 15.4 (1.8—54.3) 23.7 16.5 (6.1—51.4)
Osteoid volume % 4.51 3.01 4.05 3.03 (0.16—9.20) 4.74 3.89 (0.76—12.50)
Resorption — — —
Eroded surface % 2.53 1.62 2.58 1.77 (0.30—6.74) 2.45 1.40 (0.90—5.10)
Osteoclast surface % 0.55 0.34 0.55 0.34 (0.03—1.25) 0.52 0.49 (0.00—1.41)
Trabecular bone — — —
Trabecular volume % 17.7 4.65 18.6 47a (11.0—28.0) 14.6 4.6 (7.9—20.8)
Trabecular thickness pin 130 19 130 16 (104—164) 118 16(96—141)
Cortical bone — — —
Cortical thickness cm 0.69 0.22 0.68 0.27 (0.27—1.24) 0.74 0.40 (0.37—1.57)
Cortical porosity % 90.3 3.1 90.5 4.4 (80.1—96.3) 88.5 4.1 (84.8—96.0)
Bone dynamics — — —
Mineral appositional rate pin/day 0.59 0.59 0.54 0.57(0.00—1.89) 0.83 0.52 (0.00—1.37)
Tetracycline labeled surface mm 5.23 5.78 4.00 545a (0.00—15.20) 7.79 6.47a (0.00—16.80)
Adjusted apposition rate pin/day 0.24 0.32 0.23 0.34 (0.00—1.32) 0.26 0.28 (0.00—0.78)
Mineralization lag time days 446.2 462.1 418.5 478.8 (0.0—1000.0) 261.0 421.5 (9.5—1000.0)
Bone formation rate per unit of bone surface
pin3/pin2/yr
13.50 15.71 11.60 16.89 (0.00—52.30) 16.97 15.09 (0.00—46.10)
Bone formation rate per unit of bone volume %/yr 26.47 30.56 22.12 31.93 (0.00—95.00) 34.48 28.64 (0.00—83.40)
Bone formation rate per unit of bone tissue %/yr 5.08 6.31 4.71 7.15 (0.00—21.30) 5.57 5.49 (0.00—17.30)
Aluminum staining (0—3) 0.5 0.7 0.3 0.7 (0—2) 0.6 0.7 (0—2)
Aluminum content ppm 20.9 14.3 21.1 15.0 (6.8—52.9) —
Significant differences were only found between trabecular bone volume and tetracycline labeled surface at baseline and the year later ( P < 0.05).
In the second column from left the average values for all evaluated patients (pooled data) are presented.
turnover bone disease, it seems likely that increased osteoblast
production was involved in the increased levels of serum osteo-
calcin and that decreased renal clearance of osteocalcin was not
significant. Moreover, administration of 1,25(OH)2D3 has been
shown to induce a fall in serum osteocalcin and PTH in patients
with predialysis renal failure [61. It was therefore concluded that
elevated serum osteocalcin in uremics mainly reflect the extent of
the osteoblastic pool, which to a larger degree is dependent on the
duration and severity of the underlying renal bone disease [6]. As
vitamin D3 influences serum osteocalcin levels [24] by increasing
the transcription of the osteocalcin gene, it is important to
emphasize that none of our patients received any vitamin D3
analogues during the entire study.
Our patients were evaluated on their usual regime of CAPD
since peritoneal clearance and mass transfer of osteocalcin are
independent of dialysate osmolalities [12]. Klein et al [10] found
notably higher serum osteocalcin levels in adult CAPD patients
than in the present study. While their MT-osteocalcin was
comparable to ours [10], we found higher Cl-osteocalcin values.
However, our results indicate no correlations between Cl-osteo-
calcin and any of the measured histomorphometric parameters
(Table 4). Cl-osteocalcin is therefore of no interest as a non-
invasive marker of metabolic bone disease in patients treated by
CAPD, As the significant correlations involving dialysate osteo-
calcin (Table 4) were almost the same as serum osteocalcin, a kind
of secondary phenomenon to the dialysis treatment per se was
most likely.
Notable levels of osteocalcin in serum and dialysate have been
reported in children receiving peritoneal dialysis with osteocalcin
concentrations as much as 10% higher in the peritoneal dialysate
than in serum [8]. The difference between serum and peritoneal
dialysate levels in children and adults with end-stage renal failure
could be caused by differences in skeletal turnover. It is also of
relevance to note the possibilities that children with early onset
renal failure have a higher incidence of bone disease. Moreover,
children have a relatively high clearance per kg of body wt, which
could also influence the clearance values. In the present study
serum and dialysate levels of osteocalcin correlated significantly,
while no correlations were found between osteocalcin values in
the dialysate, inflow and drained volumes of dialysate effluent. In
contrast, Klein et at [10] did not observe any correlation between
dialysate and serum osteocalcin concentrations, whereas they, like
us, observed a significant correlation between serum osteocalcin
and MT-osteocalcin [10]. Based on this correlation Klein et al
concluded that serum osteocalcin levels among CAPD patients
should always be interpreted with MT-osteocalcin levels [10].
During the last decade the spectrum of bone histological
features in patients with renal osteodystrophy has changed, result-
ing in an increase in low turnover bone disease. In the present
study, osteitis fibrosa was found to be the predominant biopsy
diagnosis. Seven patients had adynamic lesions although none had
"status post-parathyroidectomy" or had received intensive vita-
min D3 therapy. None of our patients had extensive accumulation
of aluminum in the bone specimens. However, aluminum staining
increased during the year of the study, in agreement with the
finding that quantitative evaluation of bone aluminum content is
a less reliable and reproducible variable than histochemical
evaluation of aluminum deposition along the mineralization front
[21]. Although older age is a known risk factor for development of
low turnover bone disease, older patients in the present study had
increased bone turnover. Likewise, we found that increased time
as an uremic resulted in increased bone turnover (high osteoclast
surface and tetracycline labeled surface) probably due to calcium
depletion. This is indicated by the correlations between the
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Table 4. Correlations between osteocalcin (ost) measurements and other markers of bone metabolism and bone histomorphometrie parameters
Histomorphometric
parameters S-ost D-ost Cl-ost MT-ost PTH Ca2t Calcium Alk. phos. Al
O.Th
r 0.73 NS NS NS 0.73 NS NS NS NS
P <0.01 <0.01
OS
r NS NS NS NS NS 0.57 NS NS NS
P <0.05
ov
r NS NS NS NS NS 0.58 NS NS NS
P <0.05
ES
r 0.78 0.55 NS 0.61 0.51 NS 0.57 0.47 NS
P <0.001 <0.05 <0.01 <0.05 <0.05 <0.05
Oe.S
r 0.52 NS NS 0.47 NS NS NS NS NS
P <0.05 0.05
TBV NS NS NS NS NS NS NS NS NS
Tb.Th. NS MS MS MS NS MS NS MS MS
Ct.Th.
r NS MS MS MS MS 0.60 MS NS NS
P <0.05
CP MS MS MS MS MS NS MS MS NS
MAR
r 0.62 0.61 MS 0.67 0.82 NS 0.51 0.53 NS
P <0.01 <0.05 <0.01 <0.001 <0.05 <0.05
LS
r 0.87 0.79 NS 0.73 0.86 MS MS 0.74 MS
P <0.001 <0.001 <0.001 <0.001 <0.001
Aj.AR
r N5 0.46 NS 0.50 0.84 MS MS NS NS
P 0.05 <0.05 <0.001
MLT
r MS neg. NS neg. neg. MS neg. neg. NSP <0.01 <0.01 <0.01 <0.01 <0.01
BFR/BS
r 0.75 0.71 MS 0.72 0.82 MS NS 0.65 MS
P <0.001 <0.01 <0.001 <0.001 <0.01
BFRIBV
r 0.75 0.75 MS 0.74 0.79 NS MS 0.70 NS
P <0.001 <0.001 <0.001 <0.001 <0.01
BFRITV
r 0.79 0.65 NS 0.65 0.81 MS MS 0.60 MS
P <0.001 <0.01 <0.01 <0.001 <0.01
AIS
r neg. NS MS MS MS MS neg. MS NSP <0.05 <0.05
AIC NS MS NS MS MS MS MS MS MS
Abbreviations are: Aj.AR, adjusted apposition rate; Al, serum aluminum; AIC, aluminum content; Alk. phos., alkaline phosphatase; AdS, aluminum
staining; BFRJBS, bone formation rate per unit of bone surface; BFR/BV, bone formation rate per unit of bone volume; BFR/TV, bone formation rate
per unit of tissue volume; Calcium, total calcium; Ca2t, ionized calcium; Cl-ost, peritoneal clearance; CP, cortical porosity; Ct.Th., cortical thickness;
D-ost, dialysate osteocalcin; ES, eroded surface; LS, labeled surface; MAR, mineral appositional rate; MLT, mineralization lag time; MT,-ost,
peritoneal mass transfer; MS, non-significant; Oc.S, osteoclast surface; OS, osteoid surface; O.Th, osteoid thickness; OV, osteoid volume; PTH, intact
parathyroid hormone; r neg., negative correlation; 5-ost, serum osteocalcin; TBV, trabecular bone volume; Th.Th., trabecular bone thickness.
histomorphometric parameters, serum calcium and serum Ca2 fore not shown any sure biochemical or histological changes in
given in Table 4. bone turnover. This may be due either to the relatively small
One of the aims of the present investigation was to evaluate the number of patients undergoing two biopsies or the short time
relationship between osteocalcin and bone histomorphometry for interval. Moreover, we found that serum PTH correlated to
a non-invasive prediction of bone histology. We found that bone almost the same histomorphometric parameters as serum osteo-
biopsies taken twice with one year's interval showed a significant calcin. Multiple stepwise regression showed that serum osteocal-
increase in labeled surfaces and decrease in trabecular bone. cm and PTH levels gave supplementary information to one
While it is not surprising that patients lost bone mass during the another although PTH had lower correlation coefficients than
investigation, it is not certain that there was a real increase in bone serum osteocalcin in respect to eroded surface area. In contrast to
turnover during the year, as other measures of turnover showed this finding, Sebert at al [22] found higher correlation coefficients
no significant change. Thus, the present investigation has there- between serum osteocalcin and bone formation rate than PTH in
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Fig. 2. Correlation between measured tetracycline labeled surfaces and
predicted tetracycline labeled surfaces in patients undergoing CAPD. Tetra-
cycline labeled surfaces are given with the equation: tetracycline labeled
surfaces =
—3.15 + 0.145 X serum osteocalcin + 0.409 X dialysate
osteocalcin + 0.184 )< serum PTH; r = 0.98).
hemodialysis patients. In another study consisting of hemodia-
lyzed patients, serum osteocalcin 8 nmollliter and a mineralized
surface 3 gave a specificity of 94% and a sensitivity of 57% for
having high turnover osteopathy [25]. Likewise, serum osteocalcin
levels s4 nmol/liter seemed to reflect low turnover osteopathy
with a specificity and a sensitivity of 100% and 17%, respectively
[251. Motz [261 studied hemodialysis patients with serum osteo-
calcin measurements and bone scintigraphies. It was shown that
70% of the patients with serum osteocalcin >30 nglml showed
moderate to severe scintigraphic findings of bone disease [26].
However, the literature gives only very limited data on the
correlations of osteocalcin measurements and bone histomor-
phometry in patients undergoing CAPD or peritoneal dialysis in
general. Malluche et al [7] evaluated 30 chronically dialyzed
patients, four of whom were on CAPD. Only patients who had a
diagnostic bone biopsy were enrolled and the data of the CAPD
patients were not separated from the remaining population of
hemodialyzed patients [7]. As in the present study, Malluche et al
[7] found significant positive correlations between serum osteo-
calcin, bone formation and mineral apposition rate. Rottembourg
et al [27] evaluated 16 CAPD patients through blood studies and
bone biopsy. All patients received calcitriol and eight of them had
adynamic bone disease. Unfortunately, Rottembourg et al [27] did
not publish any data concerning possible correlations between
bone histomorphometry and osteocalcin levels. Cole, Carpenter
and Gundberg [8] evaluated serum osteocalcin concentrations in
children with metabolic bone disease. Only one patient with renal
failure receiving hemodialysis was evaluated by radiography [8]. In
a study where eight patients were treated by CAPD, Epstein et al
[9] found serum and dialysate levels of osteocalcin significantly
higher than in our patients. However, all of their patients were
taking vitamin D3 metabolites. In that study no bone biopsy
specimens were available to confirm the presence of renal os-
teodystrophy or to correlate levels of osteocalcin with bone
histomorphometry. Likewise, Gundberg et al [4] examined osteo-
calcin in infants and adolescents undergoing CAPD. As earlier
adduced, children have higher levels of osteocalcin than adults
due to growth. Moreover, no bone biopsies were performed [4].
Thus, to the best of our knowledge the present study is the first
and most comprehensive investigation of serum and dialysate
osteocalcin as well as Cl-osteocalcin and MT-osteocalcin levels
where these concentrations are correlated to bone histomor-
phometry in patients not receiving vitamin D3 analogues.
Conclusion
Serum osteocalcin was elevated at baseline and one year later.
Osteocalcin was detected in the dialysate resulting in measurable
values of Cl-osteocalcin and MT-osteocalcin but this appears to
be without clinical significance. No correlations between Clv-
osteocalcin and any of the measured histomorphometric param-
20 eters were seen. Serum and dialysate levels of osteocalcin corre-lated significantly. Serum osteocalcin was significantly correlated
to serum alkaline phosphatase and serum PTH. Dialysate osteo-
calcin and MT-osteocalcin also correlated to serum alkaline
phosphatase and serum PTH. Serum osteocalcin correlated more
or less to the same histomorphometric parameters as PTH, but
the latter had lower correlation coefficients than serum osteocal-
cm in respect to eroded surface. Significant correlations between
serum osteocalcin, bone formation and mineral apposition rate
were found. Thus, osteocalcin is a valuable non-invasive index of
metabolic bone disease in patients treated by CAPD.
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